other material
confidence high
sentiment positive
materiality 0.70
DNA X raises $2.5M in Series B Preferred, cancels $3.1M debt to meet Nasdaq equity requirement
DNA X, Inc.
- Sold 929,864 Series B Preferred shares for $2.5M cash and cancellation of $3.1M convertible note balance.
- Pro forma stockholders' equity as of July 9, 2026 is $3.798M, above Nasdaq's $2.5M minimum.
- Remaining 416,667 Series B shares expected to close by August 14, 2026.
- Company awaits Nasdaq formal determination of compliance with minimum equity rule.